Biotech Values

[lgonber]

thanks for your reply, as you have worked with AAV vectors, I am interested in your opinion, as Ia also have discussed with cardiologysts in the clinic, looking forward to FDA approval on the drug. I know you dont intend to bash my investment. And I like to hear both bull and bear thesis, I also assume there is a continuous research and improvement in vectors and things that could not be done in the past, can be done today.
To determine Mydicar's efficacy, researchers calculated changes over six months in seven different scales typically used to assess heart-failure patients. The analysis found that the high dose of Mydicar demonstrated a statistically significant improvement in heart-failure measurements compared to a placebo. Through three years of additional follow-up, the high dose of Mydicar reduced the risk of hospitalization by 82%.In the 2014 published study of CUPID-1 follow-up, researchers were able to obtain biopsies of cardiac tissue from 11 patients. In three of four patients infused with the high dose of Mydicar, persistent presence of the transferred gene was found. (3 out of fore, is not "some", is "most of them)
Breakthrough therapy designation by FDA is not handed out to anyone.